Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Buparlisib in advanced endometrial carcinoma
NCT01289041Phase 2Completed
- Sponsor
- Novartis
- Start
- Feb 2011
- Primary completion
- Mar 2014
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 2, open-label, single-arm trial of buparlisib in endometrial carcinoma, sponsored by Novartis. Primary endpoint: Best Overall Response Rate at 24 months. Started Feb 2011; status: completed.
02
Drugs
buparlisib
03
Conditions
endometrial carcinoma
Beyond the preview
Go deeper on NCT01289041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01289041.